Literature DB >> 25200264

Trends, productivity losses, and associated medical conditions among toxoplasmosis deaths in the United States, 2000-2010.

Patricia L Cummings1, Tony Kuo2, Marjan Javanbakht2, Frank Sorvillo2.   

Abstract

Few studies have quantified toxoplasmosis mortality, associated medical conditions, and productivity losses in the United States. We examined national multiple cause of death data and estimated productivity losses caused by toxoplasmosis during 2000-2010. A matched case-control analysis examined associations between comorbid medical conditions and toxoplasmosis deaths. In total, 789 toxoplasmosis deaths were identified during the 11-year study period. Blacks and Hispanics had the highest toxoplasmosis mortality compared with whites. Several medical conditions were associated with toxoplasmosis deaths, including human immunodeficiency virus (HIV), lymphoma, leukemia, and connective tissue disorders. The number of toxoplasmosis deaths with an HIV codiagnosis declined from 2000 to 2010; the numbers without such a codiagnosis remained static. Cumulative disease-related productivity losses for the 11-year period were nearly $815 million. Although toxoplasmosis mortality has declined in the last decade, the infection remains costly and is an important cause of preventable death among non-HIV subgroups. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Year:  2014        PMID: 25200264      PMCID: PMC4228893          DOI: 10.4269/ajtmh.14-0287

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

1.  Protection of human subjects.

Authors: 
Journal:  Code Fed Regul Public Welfare       Date:  1995-10-01

2.  Toxoplasmosis-associated deaths among Human Immunodeficiency Virus-infected persons in the United States, 1992-1998.

Authors:  Jeffrey L Jones; Meena Sehgal; James H Maguire
Journal:  Clin Infect Dis       Date:  2002-04-15       Impact factor: 9.079

3.  Impact of HIV infection on mortality and accuracy of AIDS reporting on death certificates.

Authors:  N A Hessol; S P Buchbinder; D Colbert; S Scheer; R Underwood; J L Barnhart; P M O'Malley; L S Doll; A R Lifson
Journal:  Am J Public Health       Date:  1992-04       Impact factor: 9.308

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

5.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

6.  Mortality and Productivity Losses From Alzheimer Disease Among US Adults Aged 40 to 64 Years, 1999 to 2010.

Authors:  Kristin Moschetti; Noel Barragan; Ricardo Basurto-Dávila; Patricia L Cummings; Frank Sorvillo; Tony Kuo
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Apr-Jun       Impact factor: 2.703

7.  Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection.

Authors:  Oluwatoyin Falusi; Audrey L French; Eric C Seaberg; Phyllis C Tien; D Heather Watts; Howard Minkoff; Eva Piessens; Andrea Kovacs; Kathryn Anastos; Mardge H Cohen
Journal:  Clin Infect Dis       Date:  2002-11-11       Impact factor: 9.079

8.  Genotypic characterization of Toxoplasma gondii strains associated with human toxoplasmosis in Spain: direct analysis from clinical samples.

Authors:  I Fuentes; J M Rubio; C Ramírez; J Alvar
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 9.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

10.  Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team.

Authors:  B J Luft; R Hafner; A H Korzun; C Leport; D Antoniskis; E M Bosler; D D Bourland; R Uttamchandani; J Fuhrer; J Jacobson
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

View more
  4 in total

Review 1.  Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.

Authors:  Hany M Elsheikha; Christina M Marra; Xing-Quan Zhu
Journal:  Clin Microbiol Rev       Date:  2020-11-25       Impact factor: 26.132

2.  Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017.

Authors:  Kathy Belk; Mark P Connolly; Lisa Schlesinger; Ruben R Ben-Harari
Journal:  Pathog Glob Health       Date:  2018-12-10       Impact factor: 2.894

3.  Mortality Patterns of Toxoplasmosis and Its Comorbidities in Tanzania: A 10-Year Retrospective Hospital-Based Survey.

Authors:  Leonard E G Mboera; Coleman Kishamawe; Evord Kimario; Susan F Rumisha
Journal:  Front Public Health       Date:  2019-02-19

4.  Transdisciplinary and social-ecological health frameworks-Novel approaches to emerging parasitic and vector-borne diseases.

Authors:  A Alonso Aguirre; Niladri Basu; Laura H Kahn; Xenia K Morin; Pierre Echaubard; Bruce A Wilcox; Val R Beasley
Journal:  Parasite Epidemiol Control       Date:  2019-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.